Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani; Julia M. Akeroyd; Vijay Nambi; Erin D. Michos; Pamela B. Morris; Khurram Nasir; Sidney C. Smith; Neil J. Stone; Laura A. Petersen; Christie M. Ballantyne

doi:10.1161/CIRCULATIONAHA.118.034993

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani
, Julia M. Akeroyd
, Vijay Nambi
, Erin D. Michos
, Pamela B. Morris
, Khurram Nasir
, Sidney C. Smith
, Neil J. Stone
, Laura A. Petersen
, Christie M. Ballantyne

Research output: Contribution to journal › Letter › peer-review

12 Citations (Scopus)

Original language	English (US)
Pages (from-to)	410-412
Number of pages	3
Journal	Circulation
Volume	139
Issue number	3
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.118.034993
Publication status	Published - 15 Jan 2019
Externally published	Yes

Keywords

cholesterol
clinical trial

Access to Document

10.1161/CIRCULATIONAHA.118.034993

Cite this

Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A., & Ballantyne, C. M. (2019). Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs. Circulation, 139(3), 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

@article{8b682036ceb8470abac09cdba894d2dd,

title = "Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs",

keywords = "cholesterol, clinical trial",

author = "Virani, \{Salim S.\} and Akeroyd, \{Julia M.\} and Vijay Nambi and Michos, \{Erin D.\} and Morris, \{Pamela B.\} and Khurram Nasir and Smith, \{Sidney C.\} and Stone, \{Neil J.\} and Petersen, \{Laura A.\} and Ballantyne, \{Christie M.\}",

note = "Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research \& Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research \& Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research \& Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research \& Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.",

year = "2019",

month = jan,

day = "15",

doi = "10.1161/CIRCULATIONAHA.118.034993",

language = "English (US)",

volume = "139",

pages = "410--412",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

Virani, SS, Akeroyd, JM, Nambi, V, Michos, ED, Morris, PB, Nasir, K, Smith, SC, Stone, NJ, Petersen, LA & Ballantyne, CM 2019, 'Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs', Circulation, vol. 139, no. 3, pp. 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

TY - JOUR

T1 - Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

T2 - Insights From the Department of Veterans Affairs

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Michos, Erin D.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Smith, Sidney C.

AU - Stone, Neil J.

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

N1 - Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.

PY - 2019/1/15

Y1 - 2019/1/15

KW - cholesterol

KW - clinical trial

UR - https://www.scopus.com/pages/publications/85060035929

U2 - 10.1161/CIRCULATIONAHA.118.034993

DO - 10.1161/CIRCULATIONAHA.118.034993

M3 - Letter

C2 - 30586689

AN - SCOPUS:85060035929

SN - 0009-7322

VL - 139

SP - 410

EP - 412

JO - Circulation

JF - Circulation

IS - 3

ER -

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Keywords

Access to Document

Other files and links

Cite this